NEWS
Paul Hastings Advises Semnur Pharmaceuticals on Closing of Business Combination With Denali Capital Acquisition
September 23, 2025
Paul Hastings LLP advised Semnur Pharmaceuticals, a clinical late-stage specialty pharmaceutical company and majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), on the closing of its previously announced business combination with Denali Capital Acquisition Corp. The combined company will operate as Semnur Pharmaceuticals Inc., and its shares of common stock and warrants are expected to trade on the OTC markets on Sept. 23, 2025, under the ticker symbols SMNR and SMNRW, respectively.
Paul Hastings previously advised Semnur on the signing of the merger agreement in September 2024.
Partners Jeff Hartlin and Elizabeth Razzano led the Paul Hastings team, which also included partner Lucas Rachuba and associates Mark Cramer, Youssef Aziz, Jenna Barba, Elizabeth Fleming, Lena Son and Daniel Jun.
More details about the transaction can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.